Literature DB >> 12062484

The selective neurokinin (NK)(1) antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study.

Françoise Lejeune1, Alain Gobert, Mark J Millan.   

Abstract

Upon acute, systemic administration, the selective, non-peptidergic NK(1) receptor antagonist, GR205,171, dose-dependently enhanced the firing rate of ventrotegmental dopaminergic neurones. Dialysate levels of dopamine were increased in the frontal cortex, but not in the striatum and nucleus accumbens, of conscious rats. These actions were stereospecific in that its less-active isomer, GR226,206, was ineffective. Further, they were selective for dopaminergic pathways inasmuch as the firing rate of dorsal raphe serotonergic neurones and dialysate levels of serotonin were unaffected by GR205,171. Activation of mesocortical dopaminergic pathways may be involved in the influence of NK(1) antagonists upon mood.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12062484     DOI: 10.1016/s0006-8993(02)02476-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

1.  Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain.

Authors:  Jarmo Hietala; Mikko J Nyman; Olli Eskola; Aki Laakso; Tove Grönroos; Vesa Oikonen; Jörgen Bergman; Merja Haaparanta; Sarita Forsback; Päivi Marjamäki; Pertti Lehikoinen; Michael Goldberg; Donald Burns; Terence Hamill; Wai-Si Eng; Alexandre Coimbra; Richard Hargreaves; Olof Solin
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

2.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 3.  Neurokinin receptors in drug and alcohol addiction.

Authors:  Jesse R Schank
Journal:  Brain Res       Date:  2020-02-15       Impact factor: 3.252

Review 4.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.